Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics ...

Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its ...

About Transcenta Therapeutics Transcenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

Galapagos offers deep value with €3B cash, a focused M&A strategy, and new leadership. Click here to read an analysis of GLPG ...

MDR, MDSAP, and FDA audits demand rigorous preparation, lifecycle traceability, and risk-based compliance for global market ...

The CNPV program significantly reduces drug review times, necessitating operational shifts for sponsors to meet compressed timelines. Sponsors must execute market access, pricing, and post-approval ...

Discover how drugs prevent, cure, and alleviate ailments. Learn about over-the-counter vs. prescription drugs and the ...